Table 1 Baseline characteristics of study cohorts
Variable | Study cohorts | p value | |
|---|---|---|---|
Other PPIs (N = 3336) | Lansoprazole (N = 1668) | ||
Age (mean ± SD) | 51.06 ± 14.77 | 52.20 ± 14.51 | 0.009 |
Gender (No., %) | 1.000 | ||
Female | 1316(39.4) | 658(39.4) | |
Male | 2020(60.6) | 1010(60.6) | |
Comorbidities (No., %) | |||
Heart failure | 136(4.1) | 53(3.2) | 0.116 |
Malignant neoplasms | 425(12.7) | 234(14.0) | 0.204 |
Hyperlipidemia | 524(15.7) | 249(14.9) | 0.472 |
Cardiovascular disease | 654(19.6) | 327(19.6) | 1.000 |
Hypertension | 1260(37.8) | 630(37.8) | 1.000 |
Chronic liver disease | 776(23.3) | 431(25.8) | 0.044 |
Chronic kidney disease | 46(1.4) | 23(1.4) | 1.000 |
Co-medications (No., %) | |||
Thiazide | 118(3.5) | 48(2.9) | 0.219 |
Beta blocking agents | 907(27.2) | 433(26.0) | 0.355 |
Statins | 422(12.6) | 211(12.6) | 1.000 |
Corticosteroids | 1183(35.5) | 609(36.5) | 0.466 |